Neuland Laboratories (524558) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 revenue rose 21.7% year-over-year to INR 444.4 crores, driven by strong CMS business performance and healthy EBITDA margins.

• Profit after tax was INR 98.3 crores, up 58% YoY, including a one-time gain of INR 20.6 crores from sale of investment property.

• The business model is transitioning from Prime APIs to a balanced mix of CMS and GDS APIs, reflecting strategic focus.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2024, were approved by the Board on August 1, 2024.

• Management expects FY25 to be a year of normalization in revenue growth and margins, with momentum anticipated to pick up from FY26 based on the project pipeline.

Financial highlights

• Total income for Q1 FY25 was INR 444.4 crores, up 21.7% year-over-year and 13.8% sequentially.

• EBITDA (excluding exceptional items) reached INR 128.6 crores with a margin of 28.9%, up 174 bps from Q1 FY24.

• PAT stood at INR 98.3 crores, including an exceptional profit of INR 20.6 crores from transfer of investment property.

• Free cash flow generated in Q1 FY25 was INR 50.9 crores, with INR 59.1 crores invested in capex.

• Net debt position is negative at INR 110.2 crores after partial debt repayment.

Outlook and guidance

• FY25 is expected to be a year of consolidation with normalized revenues and margins, as the company enters an investment phase.

• Revenue and margin growth are anticipated to accelerate from FY26, supported by new facility completion and product launches.

• Capacity addition of 19 KL at Unit 1 expected to be available for commercial production in 1–1.5 years to meet growing customer demand.

• Management remains optimistic about the long-term potential of the CMS business and continued R&D investments.